KORU Medical Q3 revenue $11.6M, up 11%; net income $0.2M, second straight positive quarter

KORU Medical Systems, Inc.

Net revenues $11.57M (+11.2% YoY); gross margin 65.2% vs 60.2%; gross profit $7.5M (+20.5%).
Domestic core revenue $8.06M (+31.6%); international core $3.08M (-16.5%); pharma services $0.42M (-27.4%).
Net income $0.2M ($0.00 diluted) vs prior-year net loss of $0.8M (-$0.02); adjusted EBITDA $1.3M vs $0.1M.
FY2026 revenue guidance narrowed to $48.0-48.5M (17-18% growth) from $47.5-48.5M; gross margin raised to 63-64%.
Signed two new sales and distribution agreements in Europe and Africa; year-end cash guidance raised to >$8.0M from >$7.5M.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.